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Charge per case Savings 
per case 
Tranexamic Acid and  
Blood Salvage Drain 
$584.69 N/A 
Tranexamic Acid and 
Constavac Drain 
$373.95 $210.74 
Tranexamic Acid and no drain $260.72 $323.97 
Estimated Total Savings in one year, considering an average  





•  Over the last 2 years, the Bone and Joint Center has focused on 
blood utilization for total knee and total hip arthroplasty. With the use 
of a blood transfusion protocol, we significantly reduced blood 
transfusion rates and standardized the approach to care.    
• As an expansion of this work, other ideas to further decrease blood 
utilization were considered.  
• The purpose of the data collection of preoperative and postoperative 
Hemoglobin (Hgb) levels was to evaluate the effect of Tranexamic 
Acid(TXA) on the average change in Hgb levels compared to Hgb 
levels of patients that did not receive the medication. In addition, a 
review of the consistency of practice for Hgb draws and review of the 
quality of patient care related to the number of lab draws, cost to the 
patient, and blood re-infusion per drain were recognized as other 
opportunities.  
• The use of a post-operative drain has been shown to be associated 
with an additional cost to the patient and hospital, increased length of 
stay, possible risk of infection, potential  increase in blood loss and 
increase in the need for a blood transfusion.  
Background 
• Varied techniques such as preoperative autologous donation, 
blood re-infusion per drain postoperatively, and blood algorithms 
have been utilized to reduce blood loss and/or the need for a 
blood transfusion after total knee arthroplasty . 
• In review of literature, one grade level A article and three grade 
level B articles, support the use of TXA to reduce the risk of 
infection, decrease length of stay, minimize postoperative blood 
loss and decrease the cost associated with blood transfusions 
via blood bank and/or drain reinfusion. 
• TXA is a synthetic antifibrinolytic agent that has successfully 
been used to reduce blood loss following total knee replacement 
and to decrease the need for a blood transfusion. This 
medication can be administered intraoperatively either 
intravenously or topically (intra-articular).  
• Through the work on a core measure for Disease Specific Care 
Certification, the blood transfusion rate for elective total knee 
and total hip replacement decreased from 20% in FY 2012 to 5% 
in FY 2013, with an estimated cost savings of $150,000.  
• Discussion at Department of Orthopedics with key stakeholders 
from perioperative services, OR, and Bone and Joint on benefits 
of TXA to reduce blood loss and blood utilization postoperatively. 
Some orthopedic surgeons initiated the use of TXA after this 
discussion and discontinued the use of a blood salvage drain or 
changed to a non re-infusable drain, constavac.  
• Acuity of patients is higher due to the drain in place and the 
need to re-infuse, time for vital sign monitoring, and removal of 
the drain. This results in increased cost related to nursing time 




• We defined our patient population by comparing 34 total 
knee arthroplasty cases of one orthopedic surgeon , 
surgery dates of February 1st to April 22nd, 2013 pre-
implementation of TXA compared to 25 cases from April 
23rd to June 25th, 2013  post-implementation of TXA. 
• We compared the average change in preoperative Hgb 
level to day after surgery level. The average change in 
Hgb level from day of surgery to day after surgery, along 
with day after surgery and post-operative day 2 were 
evaluated.  
• The overall average decrease in the Hgb level from pre-
op to POD 2 was 1.0 less in the TXA group.  
• The percent of patients  requiring a re-infusion per drain 
postoperatively  that did not receive TXA was  69% 
compared to  8% for patients that did receive TXA. Of 
the patients that did not receive TXA, 24 had a drain re-
infusion . There were only 2 patients that received TXA 
and had a drain re-infusion for 150 ml each .  
• Since December 2013, surgeons have discontinued the 
routine usage of the reinfusion drain in elective total 
knee arthroplasty. TXA is utilized in majority of these 
cases and either a non-reinfusable drain or no drain.   
• There is also a significant cost savings of salary dollars, 
due to  decreasing nursing time for preparation and re-
infusion per drain, monitoring of vitals, and 
discontinuation of the drain. On average patients 
received one reinfusion per drain initiated in a 6 hour  






Future considerations:  
•  Utilize TXA to decrease decline of Hgb level 
postoperatively and decrease drain blood loss.  
• Decrease or eliminate routine usage of a re-infusion or 
constavac drain. 
• Possibly administer TXA in other types of orthopedic 
procedures such  as fracture repair and total shoulder 
replacement. 
• Incorporate order for TXA into preop order sets to 
increase awareness and accessibility of the medication 
in OR. 
• Evaluate the need for the number of Hgb draws 
postoperatively and decrease frequency as appropriate. 
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Overall Avg. Change in Hgb from Pre-Op to POD 2 = 2.5      (N= 25) 
Overall Avg. Change in Hgb from Pre-Op to POD 2 = 3.5    (N=34) 
